An announcement from Exact Sciences ( (EXAS) ) is now available.
On April 29, 2025, Exact Sciences Corporation appointed Leslie Trigg as a Class II member of its Board of Directors, following the resignation of Kathleen Sebelius. Ms. Trigg, with over 25 years of experience in the healthcare and medical device industries, is expected to bring valuable leadership and investor relations skills to the company, potentially strengthening its market position.
Spark’s Take on EXAS Stock
According to Spark, TipRanks’ AI Analyst, EXAS is a Neutral.
Exact Sciences scores moderately due to its robust revenue growth and positive outlook, as highlighted in the earnings call. However, profitability issues, a significant impairment charge, and bearish technical indicators weigh heavily on the stock’s performance. The absence of dividends and negative earnings further affect its valuation appeal.
To see Spark’s full report on EXAS stock, click here.
More about Exact Sciences
Exact Sciences Corporation operates in the healthcare industry, focusing on medical diagnostics and cancer screening products.
YTD Price Performance: -19.91%
Average Trading Volume: 2,318,461
Technical Sentiment Signal: Buy
Current Market Cap: $8.47B
Learn more about EXAS stock on TipRanks’ Stock Analysis page.